$BDPT
BIOADAPTIVES, INC.

2023 Q2 Form 10-Q Financial Statement

#000164033423000837 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $2.339K $3.376K
YoY Change -45.88% -38.98%
Cost Of Revenue $849.00 $1.396K
YoY Change -60.86% -61.11%
Gross Profit $1.490K $1.980K
YoY Change -30.79% 1.9%
Gross Profit Margin 63.7% 58.65%
Selling, General & Admin $56.76K $20.29K
YoY Change -53.33% -85.81%
% of Gross Profit 3809.4% 1024.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $680.00 $670.00
YoY Change -97.15% -97.98%
% of Gross Profit 45.64% 33.84%
Operating Expenses $57.44K $20.96K
YoY Change -60.51% -88.11%
Operating Profit -$55.95K -$18.98K
YoY Change -60.96% -89.11%
Interest Expense $52.25K $51.06K
YoY Change -30.67% 69.65%
% of Operating Profit
Other Income/Expense, Net -$87.97K -$268.2K
YoY Change 9.22% 39.06%
Pretax Income -$143.9K -$287.2K
YoY Change -35.7% -21.77%
Income Tax
% Of Pretax Income
Net Earnings -$143.9K -$287.2K
YoY Change -35.7% -21.78%
Net Earnings / Revenue -6152.93% -8506.72%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 384.9M shares 355.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.14K $5.980K
YoY Change -19.04% -89.31%
Cash & Equivalents $40.12K $5.944K
Short-Term Investments $20.00 $30.00
Other Short-Term Assets
YoY Change
Inventory $6.487K $4.743K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.63K $10.72K
YoY Change -23.84% -82.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.644K $2.320K
YoY Change -79.83% -91.26%
TOTAL ASSETS
Total Short-Term Assets $46.63K $10.72K
Total Long-Term Assets $1.644K $2.320K
Total Assets $48.27K $13.04K
YoY Change -30.42% -85.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.394K $1.644K
YoY Change -44.31% -99.49%
Accrued Expenses $1.419K $1.019K
YoY Change -54.9% -98.61%
Deferred Revenue
YoY Change
Short-Term Debt $377.0K $357.6K
YoY Change -16.26% -16.34%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.727M $1.644M
YoY Change 10.39% 10.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.727M $1.644M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.727M $1.644M
YoY Change 10.39% 10.67%
SHAREHOLDERS EQUITY
Retained Earnings -$7.983M -$7.839M
YoY Change 10.15% 8.17%
Common Stock $57.65K $38.49K
YoY Change 644.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.679M -$1.631M
YoY Change
Total Liabilities & Shareholders Equity $48.27K $13.04K
YoY Change -30.42% -85.02%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$143.9K -$287.2K
YoY Change -35.7% -21.78%
Depreciation, Depletion And Amortization $680.00 $670.00
YoY Change -97.15% -97.98%
Cash From Operating Activities -$56.87K -$19.46K
YoY Change -21.0% -68.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 91.04K $0.00
YoY Change 38.53% -100.0%
NET CHANGE
Cash From Operating Activities -56.87K -$19.46K
Cash From Investing Activities
Cash From Financing Activities 91.04K $0.00
Net Change In Cash 34.17K -$19.46K
YoY Change -644.98% -28.31%
FREE CASH FLOW
Cash From Operating Activities -$56.87K -$19.46K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-367131 usd
CY2023Q1 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
CY2022Q1 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.01
CY2022Q4 us-gaap Inventory Net
InventoryNet
8877 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
34324 usd
CY2022Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
2990 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
409920 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
686856 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
381793 usd
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
10246 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1488815 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1488815 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25255 usd
CY2023Q1 dei City Area Code
CityAreaCode
702
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
659-8829
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001575142
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
252554765 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
384927282 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Entity File Number
EntityFileNumber
000-54949
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BioAdaptives Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2592228
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2620 Regatta Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89128
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
384927282 shares
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
42 usd
CY2022Q4 us-gaap Assets
Assets
37314 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2414 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7647 usd
CY2023Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
10246 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
38494 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6074763 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7551679 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37314 usd
CY2023Q1 us-gaap Revenues
Revenues
3376 usd
CY2022Q1 us-gaap Revenues
Revenues
5533 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1396 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
3590 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
1980 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
1943 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12036 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
105200 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
8250 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
37832 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
669 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33167 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
20955 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
176199 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-10 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-21 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
51063 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
30099 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-217139 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-162755 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-268212 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192875 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-287187 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-367131 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
267434761 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
53708187 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
108036 usd
CY2023Q1 bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1630652 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1093039 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
52017 usd
CY2022Q1 bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
10000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-367131 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-1398153 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-367131 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
217139 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
162755 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
669 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33167 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
40233 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
17442 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-10 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-21 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4134 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1178 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5541 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
89608 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1803 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19461 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61157 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1623 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
CY2022Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1623 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
15990 usd
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
50000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34010 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19461 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-27147 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82936 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5944 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55789 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
4010 usd
CY2023Q1 us-gaap Separate Account Liability Period Increase Decrease
SeparateAccountLiabilityPeriodIncreaseDecrease
35000 usd
CY2022Q1 us-gaap Separate Account Liability Period Increase Decrease
SeparateAccountLiabilityPeriodIncreaseDecrease
40000 usd
CY2023Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
108036 usd
CY2022Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
52017 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
0 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
0 usd
CY2023Q1 bdpt Issuance Series A Preferred Stock For Settlement Of Debt Related Party
IssuanceSeriesAPreferredStockForSettlementOfDebtRelatedParty
0 usd
CY2022Q1 bdpt Issuance Series A Preferred Stock For Settlement Of Debt Related Party
IssuanceSeriesAPreferredStockForSettlementOfDebtRelatedParty
0 usd
CY2023Q1 bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
0 usd
CY2022Q1 bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
10000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
32 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
874737 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
42 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
686856 usd
CY2023Q1 bdpt Retained Earning Accumulated Deficit
RetainedEarningAccumulatedDeficit
-7838866 usd
CY2023Q1 bdpt Debt Discount
DebtDiscount
35000 usd
CY2023Q1 bdpt Derivative Loss On Derivative1
DerivativeLossOnDerivative1
1363 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1644 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6939 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
300000 usd
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
300000 usd
CY2023Q1 bdpt Accrued Interest Current
AccruedInterestCurrent
108709 usd
CY2022Q4 bdpt Accrued Interest Current
AccruedInterestCurrent
101966 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1019 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1015 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
411372 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
409920 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q1 bdpt Total Convertible Notes Payable
TotalConvertibleNotesPayable
349750 usd
CY2022Q4 bdpt Total Convertible Notes Payable
TotalConvertibleNotesPayable
389440 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2414 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7647 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
347336 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
381793 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
347336 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
381793 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
10746 usd
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
12425 usd
CY2023Q1 bdpt Convertible Notes Accrued Interest
ConvertibleNotesAccruedInterest
107578 usd
CY2022Q4 bdpt Convertible Notes Accrued Interest
ConvertibleNotesAccruedInterest
100919 usd
CY2023Q1 bdpt Amortization Of Debt Discount
AmortizationOfDebtDiscount
40233 usd
CY2022Q1 bdpt Amortization Of Debt Discount
AmortizationOfDebtDiscount
17442 usd
CY2023Q1 us-gaap Debt Instrument Convertible If Converted Value In Excess Of Principal
DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
39690 usd
CY2023Q1 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4088 usd
CY2023Q1 bdpt Convertible Shares Of Common Stock
ConvertibleSharesOfCommonStock
132382517 shares
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64258 usd
CY2023Q1 bdpt Value Assigned Of Derivatives Liabilities
ValueAssignedOfDerivativesLiabilities
36363 usd
CY2023Q1 bdpt Expected Dividend Yield
ExpectedDividendYield
0 pure
CY2021 bdpt Expected Dividend Yield
ExpectedDividendYield
0 pure
CY2023Q1 bdpt Beginning Balance
BeginningBalance
686856 usd
CY2023Q1 bdpt Addition Of New Derivatives Recognized As Debt Discounts
AdditionOfNewDerivativesRecognizedAsDebtDiscounts
35000 usd
CY2023Q1 bdpt Addition Of New Derivatives Recognized As Loss On Derivatives
AdditionOfNewDerivativesRecognizedAsLossOnDerivatives
1363 usd
CY2023Q1 bdpt Settled On Issuance Of Common Stock
SettledOnIssuanceOfCommonStock
-64258 usd
CY2023Q1 bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
215776 usd
CY2023Q1 bdpt Ending Balance
EndingBalance
874737 usd
CY2023Q1 bdpt Loss On Derivative Instruments Related Convertible Notes
LossOnDerivativeInstrumentsRelatedConvertibleNotes
1363 usd
CY2022Q1 bdpt Loss On Derivative Instruments Related Convertible Notes
LossOnDerivativeInstrumentsRelatedConvertibleNotes
6335 usd
CY2023Q1 bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
215776 usd
CY2022Q1 bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
156420 usd
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
217139 usd
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
162755 usd
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2022Q4 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
CY2023Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
132382517 shares
CY2023Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
108036 usd
CY2022Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.006
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5429 usd
CY2023Q1 bdpt Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P2Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
2.35 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0131 pure
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 usd
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
15990 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
84 usd
CY2022 us-gaap Interest Paid
InterestPaid
232 usd
CY2023Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
8444 usd
CY2022Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
8444 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1131 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1047 usd
CY2023Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.04 pure

Files In Submission

Name View Source Status
bdpt-20230331_lab.xml Edgar Link unprocessable
bdpt-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bdpt-20230331_def.xml Edgar Link unprocessable
bdpt-20230331_pre.xml Edgar Link unprocessable
0001640334-23-000837-index-headers.html Edgar Link pending
0001640334-23-000837-index.html Edgar Link pending
0001640334-23-000837.txt Edgar Link pending
0001640334-23-000837-xbrl.zip Edgar Link pending
bdpt-20230331.xsd Edgar Link pending
bdpt_10q.htm Edgar Link pending
bdpt_10qimg1.jpg Edgar Link pending
bdpt_ex311.htm Edgar Link pending
bdpt_ex312.htm Edgar Link pending
bdpt_ex321.htm Edgar Link pending
bdpt_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
bdpt_10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending